Method for extracting and application of Suaeda salsa polysaccharide

Abstract

The application belongs to the technical field of traditional Chinese medicine extraction process and application, and relates to an extraction method and application of Suaeda glauca polysaccharide, and the steps comprise: drying and crushing and sieving Suaeda glauca medicinal materials, refluxing with 95% ethanol and petroleum ether, and extracting by filtration to obtain pretreated dried Suaeda glauca powder; then, deionized water is added according to the water-material ratio of 27-37 mL / g for reflux extraction, the extraction temperature is 70-80 DEG C, the extraction is performed for 2-3 h, the extraction liquid is combined, alcohol precipitation is performed with 95% ethanol, and the combined extraction liquid is placed at 4 DEG C overnight; the obtained precipitate is redissolved, rotary evaporated until no alcohol smell is left, and then freeze-dried to obtain Suaeda glauca crude polysaccharide; a Suaeda glauca crude polysaccharide solution is prepared, protein in the Suaeda glauca crude polysaccharide is removed by adding papain combined with a TCA method, and the Suaeda glauca polysaccharide is obtained. The Suaeda glauca polysaccharide extraction process is designed and optimized, and the extraction rate is increased by 2.27 times; the great potential of SGP in the aspect of heart protection is first explored, and scientific basis is provided for future clinical application of SGP.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine extraction technology and application technology, specifically relating to an extraction method and application of Suaeda salsa polysaccharide. Background Technology

[0002] Suaeda glauca Bunge, an annual plant belonging to the genus Suaeda in the family Cucurbitaceae, primarily grows in saline-alkali soils such as those found along coastlines, wastelands, canal banks, and field edges. The earliest record of Suaeda glauca's medicinal use is found in the Ming Dynasty text *Jiuhuang Bencao* (Emergency Relief Materia Medica). It is described as having a cool nature, slightly salty taste, and entering the stomach meridian. It is used to clear heat and eliminate food stagnation, primarily treating indigestion, fever, scrofula, and abdominal distension. Modern pharmacological studies have shown that Suaeda glauca possesses antioxidant properties, and it is commonly used in traditional Chinese medicine to treat hypertension and diabetes.

[0003] Currently, there are limited studies on the extraction of polysaccharides from *Suaeda salsa*, and most pharmacological activity research focuses on their antioxidant activity, neglecting areas such as cardioprotection. A review of previous literature reveals that, to date, there are no reports on the cardioprotective activity of *Suaeda salsa* polysaccharides.

[0004] Verapamil hydrochloride is commonly used clinically to treat paroxysmal supraventricular tachycardia. However, excessive use of verapamil can cause symptoms in zebrafish such as bradycardia, pericardial edema, sinus congestion, decreased cardiac output, and slowed blood flow. Zebrafish develop rapidly, have transparent embryos, and exhibit high genomic homology with humans. Their heart structure and function are highly similar to those of mammals. In recent years, verapamil hydrochloride-induced zebrafish heart injury models have been widely used in the field of screening for cardioprotective drug activities.

[0005] Based on this, the present invention proposes an optimized extraction process for Suaeda salsa polysaccharides and uses a zebrafish heart injury model induced by verapamil hydrochloride to detect the cardioprotective activity of Suaeda salsa polysaccharides. Summary of the Invention

[0006] The purpose of this invention is to address the aforementioned problems in the existing technology, and to propose an extraction method and application for Suaeda salsa polysaccharide. The extraction process for Suaeda salsa polysaccharide (SGP) was designed and optimized, resulting in a 2.27-fold increase in polysaccharide extraction rate compared to previous literature reports. This invention is the first to explore the significant potential of SGP in cardioprotective effects, providing a scientific basis for its future clinical application.

[0007] The technical solution of this invention is:

[0008] This invention provides a method for extracting polysaccharides from Suaeda salsa, comprising the following steps:

[0009] (1) Weigh the Suaeda salsa medicinal material, dry and pulverize it, sieve it, and reflux it with 3 to 10 times the amount of 95% ethanol for depigmentation treatment; then reflux it with 3 to 10 times the amount of petroleum ether for degreasing treatment; filter the pretreated residue and dry it to obtain depigmented and degreased Suaeda salsa powder.

[0010] (2) Weigh the dried Suaeda salsa powder, add deionized water at a water-to-material ratio of 27-37 mL / g and reflux extract at a temperature of 70-80℃ for 2-3 hours. Then filter and discard the residue, combine the extracts, and concentrate them to 1 / 3 of the original volume by rotary evaporation. Precipitate with 95% ethanol and place at 4℃ overnight. After precipitation, filter the sample and discard the supernatant. Wash repeatedly with 80% ethanol, then add deionized water to the precipitate to redissolve it. After rotary evaporation until there is no alcohol smell, freeze dry to obtain crude Suaeda salsa polysaccharide.

[0011] The water-to-material ratio mentioned above is any ratio within the range of 27 to 37 mL / g, such as 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1 or 37:1 (mL / g), but is not limited to the listed values. Other unlisted values ​​within this range are also applicable.

[0012] The extraction temperature is any temperature within the range of 70 to 80°C, such as 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, or 80°C, but is not limited to the listed values. Other unlisted values ​​within this range are also applicable.

[0013] The extraction time can be any time within the range of 2 to 3 hours, such as 2.0h, 2.1h, 2.2h, 2.3h, 2.4h, 2.5h, 2.6h, 2.7h, 2.8h, 2.9h, or 3.0h, but is not limited to the listed values. Other unlisted values ​​within this range are also applicable.

[0014] (3) Weigh out the crude polysaccharide powder of Suaeda salsa and prepare a crude polysaccharide solution of Suaeda salsa. Add a certain amount of papain, hydrolyze at 55℃ for 1.5h, and inactivate the enzyme at a core temperature of 100℃ for 10min. After centrifugation, take the supernatant, add a 20% TCA solution, shake for 30min, place at 4℃ for 12h, centrifuge, take the supernatant, concentrate by rotary evaporation, and freeze dry to obtain Suaeda salsa polysaccharide.

[0015] Furthermore, in step (1), the sieved Suaeda salsa powder is depigmented by refluxing twice with 5 times the amount of 95% ethanol for 2 hours each time; then, the Suaeda salsa powder is degreased by refluxing twice with 5 times the amount of petroleum ether for 2 hours each time.

[0016] Furthermore, the extraction temperature in step (2) is 77°C, the extraction time is 2.8 h, and the water-to-material ratio is 32 mL / g.

[0017] Further, in step (3), deionized water is added to the weighed Suaeda salsa crude polysaccharide powder to prepare a Suaeda salsa crude polysaccharide solution with a mass concentration of 2 mg / mL. A certain amount of papain (800 U / mg) is added to the solution to make the final enzyme activity in the solution 24000 U / mL. The solution is enzymatically hydrolyzed at 55℃ for 1.5 h and then inactivated at a core temperature of 100℃ for 10 min. Then, the solution is centrifuged at 6500 r / min for 10 min. The supernatant is taken and a 20% TCA solution is added to make the final concentration 6%. The solution is shaken for 30 min and placed at 4℃ for 12 h. The solution is then centrifuged at 6500 r / min for 10 min. The supernatant is concentrated by rotary evaporation and then freeze-dried to obtain deproteinized Suaeda salsa polysaccharide.

[0018] The present invention also provides Suaeda salsa polysaccharides prepared according to any one of the above extraction methods.

[0019] The present invention provides the use of Suaeda salsa polysaccharide prepared by any of the extraction methods described above in the preparation of products for the prevention and / or treatment of heart damage.

[0020] Furthermore, the product includes at least one of pharmaceuticals, pharmaceutical preparations, food, or health products.

[0021] Furthermore, the cardiac injury includes: pericardial edema, venous congestion, and verapamil-induced pericardial edema or venous congestion.

[0022] The present invention also provides the application of Suaeda salsa polysaccharide prepared by any of the extraction methods described above in the preparation of cardioprotective drugs.

[0023] The present invention also provides a medicament for the prevention and / or treatment of cardiac injury, comprising Suaeda salsa polysaccharide obtained by any of the extraction methods described above.

[0024] The beneficial effects of this invention are:

[0025] (1) This invention optimizes the extraction process of Suaeda salsa polysaccharide water extraction from three aspects: extraction temperature, extraction time, and water-to-material ratio. The optimal extraction conditions obtained are: extraction temperature 77℃, extraction time 2.8h, and water-to-material ratio 32mL / g. An enzyme-based combined TCA method is used to remove impurities from the crude Suaeda salsa polysaccharide. The polysaccharide extraction rate obtained under these optimal conditions is 4.98±0.14%, which is 2.27 times higher than that of existing technologies such as ultrasonic-assisted extraction.

[0026] (2) Based on a zebrafish evaluation model, this invention verified that Suaeda salsa polysaccharide (SGP) can significantly improve verapamil hydrochloride-induced cardiac injury in zebrafish. Compared with the model group, SGP at concentrations of 200, 100, and 50 μg / mL effectively improved symptoms such as pericardial edema, increased venous congestion area, and bradycardia in zebrafish, and significantly increased cardiac output and blood flow velocity. Experimental data showed that at concentrations of 200 and 100 μg / mL, SGP's effect on improving pericardial edema and venous congestion area was even better than that of the positive control drug digoxin. Attached Figure Description

[0027] Figure 1 Results of pericardial edema area and venous congestion area in zebrafish (multiplier 80×), where compared with the blank control group, # P<0.05; ## P<0.01; ### P < 0.001; compared with the model group, * P<0.05; ** P<0.01; *** P<0.001;

[0028] Figure 2 The results show the cardiac output and blood flow velocity in zebrafish, with the values ​​compared to the control group. # P<0.05; ## P<0.01; ### P < 0.001; compared with the model group, * P<0.05; ** P<0.01; *** P<0.001;

[0029] Figure 3 The results show the heart rate of zebrafish, with comparisons made to the control group. # P<0.05; ## P<0.01; ### P < 0.001; compared with the model group, * P<0.05; ** P<0.01; *** P<0.001. Detailed Implementation

[0030] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0031] To further understand the present invention, it will be further described in conjunction with the accompanying drawings and embodiments.

[0032] Example 1: Extraction and purification of Suaeda salsa polysaccharides

[0033] 1. Pretreatment of Suaeda salsa

[0034] Weigh 100.0g of *Suaeda salsa* medicinal material, dry and pulverize it, and pass it through a 60-mesh sieve. Refluxing the powder twice with 5 times its volume of 95% ethanol, 2 hours each time, for decolorization; then refluxing twice with 5 times its volume of petroleum ether, 2 hours each time, for degreasing. Filter the pretreated residue and dry it in a 45℃ oven to obtain decolorized and degreased dried *Suaeda salsa* powder.

[0035] 2. Extraction of crude polysaccharides from Suaeda salsa

[0036] Weigh 10.0 g of dried Suaeda salsa powder, add 150 mL of deionized water, and reflux at 100 °C twice for 2 hours each time. Filter and discard the drug residue. Combine the extracts from the two reflux extractions, concentrate by rotary evaporation to approximately 1 / 3 of the original volume, and precipitate with 95% ethanol overnight at 4 °C. Filter the precipitated sample, discard the supernatant, wash repeatedly with 80% ethanol three times, and redissolve the precipitate in an appropriate amount of deionized water. Rotate the sample solution until no alcohol odor remains, then freeze-dry to obtain Suaeda salsa polysaccharide.

[0037] 3. Purification of Suaeda salsa polysaccharides

[0038] Weigh out the crude polysaccharide powder of *Suaeda salsa* and add deionized water to prepare a test solution with a mass concentration of 2 mg / mL. Take the test solution and add a certain amount of papain (800 U / mg) to make the final enzyme activity in the solution 24000 U / mL. Enzymatically hydrolyze at 55℃ for 1.5 h, inactivate the enzyme at a core temperature of 100℃ for 10 min, centrifuge at 6500 r / min for 10 min, take the supernatant and add 20% TCA solution to the final concentration of 6%, shake for 30 min, place at 4℃ for 12 h, centrifuge at 6500 r / min for 10 min, take the supernatant, concentrate by rotary evaporation and freeze-dry to obtain the deproteinized *Suaeda salsa* polysaccharide powder.

[0039] Example 2: Cardioprotective activity of Suaeda salsa polysaccharide (SGP)

[0040] Two-day-old (dpf) zebrafish were selected and placed in 6-well plates, with 30 fish per well. A normal control group and seven SGP (salicylic acid probiotic) treatment groups were established, with concentrations of 50, 100, 200, 400, 500, 1000, and 2000 μg / mL. After 24 hours of incubation, photographs were taken, and the deformity rate and mortality rate of zebrafish in each group were recorded to determine the maximum tolerated concentration of SGP in zebrafish.

[0041] The results showed that zebrafish morphology was normal at 2000 μg / mL with SGP, and no significant toxicity or teratogenic effect was observed at any of the drug concentrations. Therefore, 200, 100, and 50 μg / mL were set as high, medium, and low dosages, respectively.

[0042] In this embodiment, a zebrafish cardiac injury model induced by verapamil hydrochloride was used to evaluate the cardioprotective activity of SGP by detecting five indicators: pericardial edema area, venous congestion area, heart rate, cardiac output, and blood flow velocity.

[0043] (1) Grouping and Dosing Regimen

[0044] Two-day-fifth zebrafish of uniform developmental stage were selected under a stereomicroscope and placed in 6-well plates. They were divided into a normal control group, a digoxin group (i.e., a positive control group), a model group, and high, medium, and low dose SGP groups (200, 100, and 50 μg / mL), with 30 fish in each group. The normal control group was treated with experimental water. The positive control group was pre-treated with 8 μg / mL digoxin (dissolved in DMSO) for 4 h. The three SGP dose groups were pre-treated with SGP (dissolved in experimental water) for 4 h. After drug treatment, 20 μg / mL verapamil hydrochloride was added for 20 min to induce modeling. The plates were then placed in a constant temperature incubator and cultured at 30°C.

[0045] (2) Detection of pericardial edema and venous congestion area

[0046] Ten zebrafish were randomly selected from each group and fixed onto a glass slide using methylcellulose (2.5%). Under a stereomicroscope (magnification 80×), the zebrafish were adjusted to a lateral recumbent position with both eyes and body segments overlapping to fully expose the atria and ventricles. The zebrafish were observed and photographed under white light. The pericardial edema area and venous congestion area of ​​the zebrafish were measured using ImageJ software.

[0047] Results of pericardial edema area and venous congestion area:

[0048] like Figure 1 As shown, compared with the control group, the model group of zebrafish exhibited significant pericardial edema and subyolk sac congestion (P<0.001, P<0.001), indicating that the zebrafish cardiac injury model was successfully established. Compared with the model group, SGP at concentrations of 200, 100, and 50 μg / mL significantly improved the area of ​​pericardial edema (P<0.001, P<0.001, P<0.01) and venous congestion (P<0.001, P<0.001, P<0.001) in zebrafish. Figure 1 A and Figure 1 B). After treatment with 8 μg / mL digoxin, the pericardial edema area and venous congestion area in zebrafish decreased by 19.2% and 70.0%, respectively, showing a statistically significant difference compared with the model group (P<0.001). Figure 1As shown in C, after treatment with 200, 100, and 50 μg / mL SGP, the pericardial edema area of ​​zebrafish decreased by 31.3%, 26.4%, and 14.1%, respectively, and the venous congestion area decreased by 74.4%, 81.1%, and 51.8%, respectively. At concentrations of 200 and 100 μg / mL, the effect of SGP was superior to that of the positive control drug digoxin (P<0.001).

[0049] (3) Detection of blood flow velocity and cardiac output

[0050] Ten zebrafish were randomly selected from each group and fixed onto a glass slide with 2.5% methylcellulose. The fish were then positioned in a lateral recumbent position and observed under a stereomicroscope (160× magnification). Blood flow images were acquired within 15 seconds using the Zebra BloodFlow System (v 3.4.6, Viewpoint). Cardiac output and blood flow velocity were analyzed using ZebraBlood™ software.

[0051] Cardiac output and blood flow velocity results:

[0052] like Figure 2 As shown, compared with the control group, verapamil hydrochloride can significantly reduce cardiac output and blood flow velocity in zebrafish (P<0.001, P<0.001), indicating that the zebrafish heart injury model has been successfully established.

[0053] Treatment with 8 μg / mL digoxin and 200, 100, and 50 μg / mL SGP (P<0.01, P<0.05, P<0.05, P<0.05) significantly increased cardiac output in zebrafish. Figure 2 A) The blood flow velocity in zebrafish was significantly increased (P<0.01, P<0.05, P<0.01, P<0.05). Figure 2 B), compared with the model group, showed a statistically significant difference.

[0054] (4) Heart rate detection

[0055] Ten zebrafish were randomly selected from each group and their heart status was observed under a stereomicroscope (magnification 40×). The heart rate of each group of zebrafish was recorded by manual counting over 1 minute.

[0056] Heart rate results:

[0057] The heart rate results of each group of zebrafish are as follows: Figure 3 As shown, the heart rate of zebrafish in the model group was significantly reduced, which was statistically different from that in the control group (P<0.001), indicating that the zebrafish heart injury model was successfully established.

[0058] Treatment with 8 μg / mL digoxin significantly increased the heart rate of zebrafish (P<0.001) compared to the model group. SGP at concentrations of 200, 100, and 50 μg / mL (P<0.001, P<0.001, P<0.001) all showed a dose-dependent increase in zebrafish heart rate.

[0059] Comparative Example 1

[0060] The difference from Example 1 is that in step 3, the purification of Suaeda salsa polysaccharide, protein was removed using the TCA method.

[0061] Weigh out the crude polysaccharide powder from *Suaeda salsa* and add deionized water to prepare a test solution with a mass concentration of 2 mg / mL. Take 50 mL of the *Suaeda salsa* polysaccharide test solution and add 20% TCA solution to a final concentration of 6%. Shake for 30 min, incubate at 4℃ for 12 h, centrifuge at 6500 r / min for 10 min, and collect the supernatant. Calculate the polysaccharide retention rate and protein removal rate.

[0062] Comparative Example 2

[0063] The difference from Example 1 is that in step 3, the purification of Suaeda salsa polysaccharide, the protein was removed using the Sevage method.

[0064] Weigh out the crude polysaccharide powder from *Suaeda salsa* and add deionized water to prepare a test solution with a mass concentration of 2 mg / mL. Take 50 mL of the 2 mg / mL SGP test solution and prepare Sevage reagent by mixing chloroform and n-butanol at a ratio of 5:1 (V:V). Mix the Sevage reagent and the test solution at a ratio of 1:5 and shake for 10–20 min. Calculate the polysaccharide retention rate and protein removal rate of the supernatant after treatment.

[0065] Comparative Example 3

[0066] The difference from Example 1 is that in step 3, the purification of Suaeda salsa polysaccharide, the protein is removed by papain method.

[0067] Weigh out the crude polysaccharide powder from *Suaeda salsa* and add deionized water to prepare a test solution with a mass concentration of 2 mg / mL. Take 50 mL of the test solution and add different amounts of papain (800 U / mg) to achieve a final enzyme activity of 24000 U / mL. Incubate at 55℃ for 1.5 h, and then inactivate the enzyme at a core temperature of 100℃ for 10 min. After centrifugation at 6500 r / min for 10 min, collect the supernatant and calculate the polysaccharide retention rate and protein removal rate.

[0068] Comparative Example 4

[0069] The difference from Example 1 is that in step 3, the purification of Suaeda salsa polysaccharide, the protein is removed by repeated freeze-thaw cycles.

[0070] Weigh out the crude polysaccharide powder from *Suaeda salsa* and add deionized water to prepare a test solution with a mass concentration of 2 mg / mL. Take 50 mL of the 2 mg / mL *Suaeda salsa* polysaccharide test solution, freeze it at -80℃ (for more than 4 hours), remove it, thaw it at room temperature, centrifuge it at 4000 r / min for 10 min to remove the precipitate, and take the supernatant. Calculate the polysaccharide retention rate and protein removal rate.

[0071] Experimental Example 2

[0072] Determination of polysaccharide retention rate and protein removal rate

[0073] A protein standard curve was established using the Coomassie Brilliant Blue method. 100.0 mg of Coomassie Brilliant Blue G-250 was accurately weighed and dissolved in 50 mL of 95% anhydrous ethanol by sonication. After centrifugation at 2000 rpm for 10 min, the supernatant was mixed with 100 mL of 85% (v / v) phosphate, and the volume was brought to 1000 mL with deionized water. The mixture was stored at 4℃. 10.0 mg of standard bovine serum albumin (BSA) was accurately weighed and brought to 100 mL with deionized water. 1, 2, 3, 4, 5, and 6 mL of each of the above solutions were placed in 10 mL volumetric flasks, and the volume was brought to 10 mL with deionized water. 1 mL of each diluted standard solution was placed in a colorimetric tube, 5 mL of Coomassie Brilliant Blue solution was added, and the mixture was stirred. The reaction was allowed to proceed at room temperature for 10 min, and the absorbance (A) was measured at 595 nm. Deionized water was used as a blank control. A protein standard curve was plotted.

[0074] The protein removal rate of the Suaeda salsa polysaccharides treated with different protein removal methods in Examples 1 and Comparative Examples 1-4 was calculated according to the following formula (1), and the polysaccharide retention rate was calculated according to the following formula (2):

[0075] Protein removal rate (%) = (C0×V0-C1×V1) / (C0×V0)×100% (2)

[0076] In formula (2): C1 represents the protein concentration (μg / mL) in the test solution after protein removal; V1 represents the volume (mL) of the test solution after protein removal; C0 represents the protein concentration (μg / mL) in the original test solution; and V0 represents the volume (mL) of the original test solution.

[0077] Polysaccharide retention rate (%) = (C M ×V M ) / (C m ×V m )×100%(3)

[0078] In equation (3): CM V represents the mass concentration (μg / mL) of Suaeda salsa polysaccharide in the test solution after protein removal; M Indicates the volume (mL) of the test solution after protein removal; C m V represents the mass concentration (μg / mL) of Suaeda salsa polysaccharide in the original test solution; m Indicates the original volume (mL) of the test solution.

[0079] The calculation results are shown in Table 1 below:

[0080] Table 1. Protein removal rate and polysaccharide retention rate of Suaeda salsa polysaccharides in Example 1 and Comparative Examples 1-4

[0081] Example 1 94.52％ 87.92％ Comparative Example 1 63.36％ 68.88％ Comparative Example 2 53.35％ 86.40％ Comparative Example 3 92.96％ 86.88％ Comparative Example 4 50.15％ 63.38％

[0082] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or make equivalent substitutions for some of the technical features. Any modifications, equivalent substitutions, alterations, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. The application of Suaeda salsa polysaccharide in the preparation of drugs for the prevention and / or treatment of cardiac injury, characterized in that, The extraction method of the Suaeda salsa polysaccharide includes the following steps: (1) Weigh the Suaeda salsa medicinal material, dry and pulverize it, sieve it, and reflux it with 3 to 10 times the amount of 95% ethanol for depigmentation treatment; then reflux it with 3 to 10 times the amount of petroleum ether for degreasing treatment; filter the pretreated residue and dry it to obtain depigmented and degreased Suaeda salsa powder. (2) Weigh the dried Suaeda salsa powder, add deionized water at a water-to-material ratio of 27-37 mL / g for reflux extraction, the extraction temperature is 70-80 ℃, the extraction time is 2-3 h, then filter to remove the residue, combine the extracts, concentrate to 1 / 3 of the original volume by rotary evaporation, precipitate with 95% ethanol, and place overnight at 4 ℃; filter the sample after precipitation to remove the supernatant, wash repeatedly with 80% ethanol, then add deionized water to the obtained precipitate to redissolve, rotary evaporate the solution until there is no alcohol smell, and freeze dry to obtain crude Suaeda salsa polysaccharide; (3) Weigh out the crude polysaccharide powder of Suaeda salsa and prepare a crude polysaccharide solution of Suaeda salsa. Add a certain amount of papain, hydrolyze at 55 ℃ for 1.5 h, and inactivate the enzyme at a core temperature of 100 ℃ for 10 min. After centrifugation, take the supernatant, add 20% TCA solution, shake for 30 min, place at 4 ℃ for 12 h, centrifuge, take the supernatant, concentrate by rotary evaporation, and freeze dry to obtain Suaeda salsa polysaccharide.

2. The application according to claim 1, characterized in that, In step (1), the sieved Suaeda salsa powder is depigmented by refluxing twice with 5 times the amount of 95% ethanol for 2 hours each time; then the Suaeda salsa powder is degreased by refluxing twice with 5 times the amount of petroleum ether for 2 hours each time.

3. The application according to claim 1, characterized in that, The extraction temperature in step (2) is 77 °C, the extraction time is 2.8 h, and the water-to-material ratio is 32 mL / g.

4. The application according to claim 1, characterized in that, In step (3), deionized water is added to the weighed Suaeda salsa crude polysaccharide powder to prepare a Suaeda salsa crude polysaccharide solution with a mass concentration of 2 mg / mL. A certain amount of papain with an enzyme activity of 800 U / mg is added to the solution to make the final enzyme activity in the solution 24000 U / mL. The solution is enzymatically hydrolyzed at 55 ℃ for 1.5 h and then inactivated at a core temperature of 100 ℃ for 10 min. Then, the solution is centrifuged at 6500 r / min for 10 min. The supernatant is taken and a 20% TCA solution is added to the solution to make the final concentration 6%. The solution is shaken for 30 min and placed at 4 ℃ for 12 h. The solution is then centrifuged at 6500 r / min for 10 min. The supernatant is concentrated by rotary evaporation and then freeze-dried to obtain deproteinized Suaeda salsa polysaccharide.

5. The application according to claim 1, characterized in that, The cardiac injuries include: pericardial edema and venous congestion.

6. A medicament for the prevention and / or treatment of cardiac injury, characterized in that, It includes the polysaccharide of *Ligusticum striatum* as described in any one of claims 1-5.

Images